Piper Sandler analyst Adam Maeder raised the firm’s price target on Abbott (ABT) to $145 from $133 and keeps an Overweight rating on the shares. The firm notes Abbott reported Q1 results that beat on adjusted EPS with reported revenue coming in slightly below consensus, which Piper sees as primarily a function of weaker than expected COVID-testing sales. More importantly, Abbott turned in +6.9% year-over-year organic growth and +8.3% year-over-year organic growth, including +12.6% ex-FX in medical devices-the latter two better than the firm modeled.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating
- Abbott price target raised to $145 from $135 at Stifel
- Abbott Laboratories: Strong Growth and Resilience Justify Buy Rating
- Abbott price target raised to $147 from $136 at Wells Fargo
- Abbott price target raised to $159 from $158 at Barclays